Vistagen Therapeutics, Inc. reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported revenue was USD 0.4114 million compared to USD 0.1796 million a year ago. Net loss was USD 6.35 million compared to USD 9.76 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 1.42 a year ago.
For the nine months, revenue was USD 0.8667 million compared to negative revenue of USD 0.4029 million a year ago. Net loss was USD 19.84 million compared to USD 47.02 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to USD 6.82 a year ago.